Posology : מינונים

4.2   Posology and method of administration
Imitrex Injection should not be used prophylactically. The recommended dose of Imitrex should not be exceeded.

It is recommended to start the treatment at the first sign of a migraine headache or associated symptoms such as nausea, vomiting or photophobia. It is equally effective at whatever stage of the attack it is administered.

The efficacy of sumatriptan is independent of the duration of the attack when starting treatment. Administration during a migraine aura prior to other symptoms occurring may not prevent the development of a headache.

Imitrex Injection should be injected subcutaneously using an auto-injector.
Patients should be advised to observe strictly the instruction leaflet for the Imitrex auto-injector especially regarding the safe disposal of syringes and needles.

Migraine:

Adult: The recommended adult dose of Imitrex is a single 6mg subcutaneous injection.
If a patient does not respond to the first dose of sumatriptan, a second dose should not be taken for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. Sumatriptan injection may be taken for subsequent attacks.

If the patient has responded to the first dose, but the symptoms recur a second dose may be given in the next 24 hours, provided that there is a minimum interval of 1 hour between the two doses.

The maximum dose in 24 hours is two 6mg injections (12mg).

Imitrex is recommended as monotherapy for the acute treatment of migraine and should not be given concomitantly with ergotamine or derivatives of ergotamine (including methysergide) (see section 4.3).


Cluster headache:
Adult:

The recommended adult dose is a single 6mg subcutaneous injection for each cluster attack. The maximum dose in 24 hours is two 6mg injections (12mg) with a minimum interval of one hour between the two doses.

Children and Adolescents (under 18 years of age):

Sumatriptan Injection is not recommended for use in children and adolescents due to insufficient data on safety and efficacy.

Older people (over 65):

Experience of the use of Imitrex Injection in patients aged over 65 years is limited. The pharmacokinetics do not differ significantly from a younger population but, until further clinical data are available, the use of Sumatriptan in patients aged over 65 years is not recommended.